Noakes M, Nestel P J, Clifton P M
CSIRO Division of Human Nutrition, Adelaide, Melbourne, Australia.
Am J Clin Nutr. 1996 Jan;63(1):42-6. doi: 10.1093/ajcn/63.1.42.
Intake of milk and butter has been clearly associated with higher coronary heart disease rates in different countries and this is likely to be mediated by the hypercholesterolemic effect of dairy fat. Fat-modified dairy products are an innovation involving a technology in which protected unsaturated lipids are fed to ruminants resulting in milk and tissue lipids with reduced saturated fatty acids. We examined the impact of these novel dairy fats on plasma lipids in a human dietary trial. Thirty-three men and women participated in an 8-wk randomized crossover trial comparing fat-modified with conventional dairy products. The trial consisted of a 2-wk low-fat baseline period followed by two 3-wk intervention phases. During the test periods, the fat-modified products resulted in a significant 0.28-mmol/L (4.3%) lowering of total cholesterol (P < 0.001). Most of this decrease was in LDL cholesterol, which decreased by 0.24 mmol/L (P < 0.001) whereas HDL cholesterol and triacylglycerols remained essentially unchanged. This alteration in the fatty acid profile of dairy products, if applied to populations typical of developed Western countries, represents a potential strategy to lower the risk of coronary heart disease without any appreciable change in customary eating patterns.
在不同国家,牛奶和黄油的摄入量与较高的冠心病发病率明显相关,这可能是由乳制品脂肪的高胆固醇血症效应介导的。脂肪改良乳制品是一项创新,涉及一种技术,即向反刍动物投喂受保护的不饱和脂质,从而使牛奶和组织脂质中的饱和脂肪酸减少。我们在一项人体饮食试验中研究了这些新型乳制品脂肪对血浆脂质的影响。33名男性和女性参与了一项为期8周的随机交叉试验,比较了脂肪改良乳制品和传统乳制品。该试验包括一个为期2周的低脂基线期,随后是两个为期3周的干预阶段。在测试期间,脂肪改良产品使总胆固醇显著降低了0.28 mmol/L(4.3%)(P < 0.001)。这种降低大部分是低密度脂蛋白胆固醇的降低,其降低了0.24 mmol/L(P < 0.001),而高密度脂蛋白胆固醇和三酰甘油基本保持不变。如果将乳制品脂肪酸组成的这种改变应用于典型的西方发达国家人群,这代表了一种在不显著改变习惯饮食模式的情况下降低冠心病风险的潜在策略。